港股異動 | 金斯瑞生物科技(1548.HK)大漲超8% 績後獲投行唱好
格隆匯4月1日丨金斯瑞生物科技(1548.HK)漲幅擴大至8.19%,報14.8港元,暫成交1.82億港元,總市值289.2億港元。
金斯瑞生物科技日前公佈,2020年收入約為3.9億美元,較去年同期增加42.9%;非細胞治療業務板塊收入大幅增長45.9%,達到3.15億美元,創下過去5年最快增速;細胞療法業務的毛利約為75.7百萬美元,同比增長31.9%。中信建投指出,公司業績符合預期,細胞治療商業化漸近。考慮到公司細胞療法龍頭地位,維持增持評級。
格隆匯今日發表文章《金斯瑞生物科技(01548.HK):營收增長43%,非細胞治療超預期,研發將迎收穫期》提到,非細胞治療業務與細胞療法業務兩大因素相互疊加,將有望為公司帶來新一輪週期性上漲,值得關注與期待。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.